Foundation Fighting Blindness
Podcast image
VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
2 mins; March 26, 2026
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
2 mins; March 24, 2026
Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa
2 mins; March 11, 2026
Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial
2 mins; March 02, 2026
Eye on the Cure Podcast | Episode 100: BEST OF
35 mins; February 27, 2026
SparingVision Completes Dosing in Gene-Agnostic Therapy Trial for Retinitis Pigmentosa (RP)
2 mins; February 11, 2026
Blind & Beyond Radio Spotlight: Jason Menzo on Vision Research and Advocacy
15 mins; February 08, 2026
Eye on the Cure Podcast | Episode 99: Dr. Prem Subramanian
28 mins; February 06, 2026
Opus Genetics Receives Funding for Gene Therapy Clinical Trial for MERTK-Related RP
2 mins; January 28, 2026
AAVantgarde Completes Enrollment in Retinal Gene Therapy Trial for Usher Syndrome Type 1B
2 mins; January 16, 2026
SpliceBio Begins Dose-Expansion Phase of Clinical Trial for Stargardt Disease Protein Splicing Therapy
3 mins; January 13, 2026
Eye on the Cure Podcast | Episode 98: Jonathan & Josh Steinberg
47 mins; January 09, 2026
Eye on the Cure Podcast | Episode 97: Lindsey Rambo
39 mins; December 19, 2025
Beacon Therapeutics Launches Clinical Trial for Bilateral Administration of XLRP Gene Therapy
2 mins; December 18, 2025
Eye on the Cure Podcast | Episode 96: Dr. Deniz Dalkara
43 mins; December 05, 2025
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
3 mins; December 02, 2025
Opus Genetics Launches Gene Therapy Clinical Trial for Best Disease
2 mins; November 14, 2025
Eye on the Cure Podcast | Episode 95: Greta Streimikyte
20 mins; November 14, 2025
Eye on the Cure Podcast | Episode 94: Dr. Victoria Claire
53 mins; October 31, 2025
SparingVision Launches Clinical Trial for Therapy to Re-Activate Dormant Cones in Advanced RP
4 mins; October 28, 2025
Eye on the Cure Podcast | Episode 93: Sam Seavey
41 mins; October 17, 2025
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
3 mins; October 02, 2025
Opus Reports Vision Improvements for Three Pediatric Patients in Phase 1/2 Clinical Trial for LCA5 Gene Therapy
4 mins; September 30, 2025
Eye on the Cure Podcast | Episode 92: Lance Baldo, MD
30 mins; September 26, 2025
Agnes Gund – Renowned Philanthropist, Social Justice Champion, and Art Patron – Passes Away
2 mins; September 22, 2025
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
3 mins; September 12, 2025
Eye on the Cure Podcast | Episode 91: Dr. George Magrath
22 mins; September 05, 2025
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
2 mins; August 22, 2025
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
3 mins; August 20, 2025
Eye on the Cure Podcast | Episode 90: Dr. Christina Ohnsman
27 mins; August 08, 2025
Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial
3 mins; August 06, 2025
Eye on the Cure Podcast | Episode 89: Dr. Christine Curcio
37 mins; July 25, 2025
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
1 min; July 21, 2025
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
2 mins; July 14, 2025
Eye on the Cure Podcast | Episode 88: Richard Small
25 mins; July 11, 2025
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
4 mins; July 09, 2025
Eye on the Cure Podcast | Episode 87: Dr. Philip Beales
18 mins; June 13, 2025
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
31 mins; May 23, 2025
J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
2 mins; May 15, 2025
ARVO 2025 Highlight: PYC Reports Encouraging Phase 1/2 Clinical Trial Results for its RNA Therapy Targeting RP (PRPF31 Mutations)
4 mins; May 13, 2025
ARVO 2025 Highlight: Atsena’s XLRS Gene Therapy Provides Vision and Structural Improvements in Phase 1/2 Clinical Trial
4 mins; May 12, 2025
ARVO 2025 Highlight: Beacon Reports Encouraging Results for Second Eyes Dosed in Clinical Trial for XLRP Gene Therapy
3 mins; May 09, 2025
Eye on the Cure Podcast | Episode 85: Cindy Elden
28 mins; May 09, 2025
Eye on the Cure Podcast | Episode 84: Contact Congress
35 mins; April 01, 2025
Eye on the Cure Podcast | Episode 83: Michel Michaelides
33 mins; March 19, 2025
Luxa Reports Vision Improvements in Clinical Trial of its RPE Stem Cell Therapy for Dry AMD
4 mins; March 10, 2025
Neurotech’s Encapsulated Cell Technology Receives FDA Approval for Treatment of MacTel
2 mins; March 06, 2025
Eye on the Cure Podcast | Episode 82: Dr. Aaron Nagiel
32 mins; March 04, 2025
Adverum Advancing Wet AMD Gene Therapy into Phase 3 Clinical Trials
3 mins; February 27, 2025
LCA4 Gene Therapy Restores Meaningful Vision for Blind Children
3 mins; February 23, 2025
Eye on the Cure Podcast | Episode 81: Ricky Enger
49 mins; February 19, 2025
RD Fund Invests in Perceive Pharma for Development of Neuroprotective Therapies
2 mins; February 17, 2025
Harriet Finkelstein, Foundation Angel, Passes Away
3 mins; February 04, 2025
Eye on the Cure Podcast | Episode 80: Aniz Girach, MD
26 mins; January 24, 2025
Atsena to Launch Part B of Phase 1/2 Clinical Trial for XLRS Gene Therapy
4 mins; January 09, 2025
Eye on the Cure Podcast | Episode 79: Damon Lembi
35 mins; January 05, 2025
ViGeneron Receives FDA Authorization to Launch Clinical Trial for mRNA Trans-splicing Gene Therapy for Stargardt Disease
3 mins; December 19, 2024
Eye on the Cure Podcast | Episode 78: Dr. Sheldon Rowan
40 mins; December 16, 2024
SpliceBio Receives FDA Clearance to Launch Clinical Trial for Stargardt Disease Protein Splicing Therapy
2 mins; December 15, 2024
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
3 mins; December 11, 2024
Eye on the Cure Podcast | Episode 77: Dr. Bob Bell
32 mins; December 03, 2024
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
3 mins; November 12, 2024
Eye on the Cure Podcast | Episode 76: The Lemay-Pelletier Family
28 mins; November 11, 2024
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
2 mins; October 29, 2024
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
3 mins; October 28, 2024
Eye on the Cure Podcast | Episode 75: Sharon King
37 mins; October 25, 2024
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
2 mins; October 23, 2024
#ShareYourVision | White Cane Day
36 secs; October 15, 2024
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
2 mins; October 11, 2024
#ShareYourVision this Blindness Awareness Month | Jessie’s Story
59 secs; October 11, 2024
Eye on the Cure Podcast | Episode 74: Dr. Kia Washington
34 mins; October 11, 2024
#ShareYourVision | What do you want others to know about your unique vision?
35 secs; October 10, 2024
Vision: A Memoir of Blindness and Justice — A New York Times Editor’s Pick
2 mins; September 26, 2024
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
3 mins; September 23, 2024
Eye on the Cure Podcast | Episode 73: Dr. Zuhal Butuner
19 mins; September 20, 2024
AAVantgarde Bio’s Dual-Vector USH1B Gene Therapy Moves into Phase 1/2 Clinical Trial
3 mins; September 18, 2024
Nanoscope Planning Phase 3 Trial of its Optogenetic Therapy for People with Stargardt Disease
2 mins; September 17, 2024
Eye on the Cure Podcast | Episode 72: Hannah Scanga
41 mins; August 23, 2024
Eye on the Cure Podcast | Episode 71: Dr. Leonide Saad
34 mins; August 09, 2024
Beacon Story | Para triathlete Deb Chucoski
11 mins; August 06, 2024
AREDS Formula Reduces Risk of Visual Acuity Loss for People with Geographic Atrophy
2 mins; July 30, 2024
Eye on the Cure Podcast | Episode 70: Karen Petrou
22 mins; July 26, 2024
VISIONS 2024 | Karen Petrou "Vision for the Future"
20 mins; July 19, 2024
VISIONS 2024 | Tribute, Awards and Closing
57 mins; July 19, 2024
VISIONS 2024 | Eye Health and Nutrition
66 hours 46 mins; July 19, 2024
VISIONS 2024 | Gene Agnostic Therapeutic Approaches
64 hours 58 mins; July 19, 2024
VISIONS 2024 | Clinical Trials: What Should You Know?
67 hours 6 mins; July 19, 2024
VISIONS 2024 | Emerging Technologies
68 hours 14 mins; July 19, 2024
VISIONS 2024 | Genetic Therapies: Gene Therapy and Genome Editing
55 mins; July 19, 2024
VISIONS 2024 | Stem Cells and Regenerative Medicine (session two)
50 mins; July 19, 2024
VISIONS 2024 | Stem Cells and Regenerative Medicine (session one)
51 mins; July 19, 2024
VISIONS 2024 | Optogenetics for Sight Restoration (session one)
57 mins; July 19, 2024
VISIONS 2024 | Optogenetics for Sight Restoration (session two)
64 hours 34 mins; July 19, 2024
VISIONS 2024 | Inherited Retinal Disease Genetics: Testing and Registries
63 hours 40 mins; July 19, 2024
VISIONS 2024 | Clinical Trial Readiness
65 hours 17 mins; July 19, 2024
VISIONS 2024 | Navigating Air Travel—A Southwest Airlines Perspective
60 hours 57 mins; July 19, 2024
VISIONS 2024 | My Advocacy. My Choice.
64 hours 2 mins; July 19, 2024
VISIONS 2024 | Fireside Chat with Judge David Tatel
28 mins; July 19, 2024
VISIONS 2024 | An In-Depth Process of Applying for a Guide Dog
58 mins; July 19, 2024
VISIONS 2024 | Low Vision Aids and Devices
69 hours 53 mins; July 19, 2024